News
NVS
160.32
-1.80%
-2.94
Novartis AG (NOVN) Gets a Hold from Berenberg Bank
TipRanks · 1d ago
Novartis releases long-term data for ianalumab in Sjögren’s disease
Seeking Alpha · 1d ago
Novartis' Ianalumab Shows Continued Benefits In Two-Year Sjögren's Study
NASDAQ · 1d ago
PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.
Barron‘s · 1d ago
PepGen Stock Doubles in One Session - Here's Why
Benzinga · 1d ago
Novartis presents long-term results from ongoing NEPTUNUS extension study
TipRanks · 1d ago
Novartis AG (NOVN) Gets a Sell from Deutsche Bank
TipRanks · 2d ago
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
NASDAQ · 2d ago
Trump's Plan to Lower Drug Prices in U.S. Is Leading to Fewer New Drugs in Europe
The Wall Street Journal · 2d ago
FDA warns of NAION vision loss risk with GLP-1 RA drugs
TipRanks · 2d ago
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
NASDAQ · 3d ago
Weekly Report: what happened at NVS last week (1102-1106)?
Weekly Report · 3d ago
Novartis AG (NOVN) Gets a Hold from Barclays
TipRanks · 3d ago
Jefferies Keeps Their Hold Rating on Novartis AG (NOVN)
TipRanks · 3d ago
Weekend Fly By: Top five stock stories
TipRanks · 3d ago
Novartis to discontinue development of pelacarsen, Bloomberg says
TipRanks · 3d ago
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Seeking Alpha · 4d ago
FDA Investigates Cancer Risk Associated With Novartis' Zolgensma Gene Therapy
NASDAQ · 5d ago
Novartis price target raised to CHF 150 from CHF 135 at Citi
TipRanks · 5d ago
Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split
NASDAQ · 5d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.